[The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].

Abstract

40 patients with benign prostatic hyperplasia (BPH) were treated with the alpha-blocker alfuzosin which was administered per os twice a day in a dose 5 mg. The treatment brought about a decrease of the mean symptom score from 19.6 to 12.2, of quality of life from 5.2 to 2.1, of residual urine from 152 to 82 ml. Mean and maximal urinary flow rates rose by 35 and 45%, respectively. The level of prostate-specific antigen over the treatment course did not change. The findings of the trial evidence for high efficacy of alfuzosin in the treatment of urination disorders in BPH patients.

• Authors: E B Mazo, I A Matushevskiĭ, Iu Iu Nikitin
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 69 Issue 10 Pg. 79-82 ( 1997) ISSN: 0040-3660 [Print] Russia (Federation)
• Vernacular Title: Lechenie bol'nykh s dobrokachestvennoĭ giperplazieĭ predstatel'noĭ zhelezy selektivnym al'fa-blokatorom al'fuzozinom.
• PMID: 9471799 (Publication Type: English Abstract, Journal Article)

Chemical References

• Adrenergic alpha-Antagonists
• Quinazolines
• alfuzosin

Topics

• Adrenergic alpha-Antagonists (pharmacokinetics, therapeutic use)
• Aged
• Aged, 80 and over
• Drug Evaluation
• Humans
• Male
• Middle Aged
• Prostatic Hyperplasia (diagnosis, drug therapy, metabolism)
• Quality of Life
• Quinazolines (pharmacokinetics, therapeutic use)
• Time Factors